Phase IIa study of pharmacokinetics and pharmacodynamics, to confirm the inhibitory effect of temsirolimus on the mTOR pathway in endometrial cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2015
At a glance
- Drugs Temsirolimus (Primary)
- Indications Endometrial cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms POEM
- 10 Jun 2017 Biomarkers information updated
- 13 Apr 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 24 Apr 2012 New trial record